Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal fentanyl vs. Actiq for breakthrough cancer pain
NCT00496392Phase 3Completed
- Sponsor
- Nycomed
- Start
- Jan 2007
- Primary completion
- Aug 2008
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fentanyl citrate nasal spray in breakthrough pain (2 arms), sponsored by Nycomed. Primary endpoint: Time to onset of meaningful pain relief recorded by stopwatch at 26 weeks. Started Jan 2007; status: completed.
02
Drugs
fentanyl citrate nasal spray
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT00496392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496392.